Impact of National Guidelines for Cholesterol Risk Factor Screening: The Framingham Offspring Study

JAMA: The Journal of the American Medical Association

Volumn 262, Issue 1, 1989, Pages 41-44

  Wilson, Peter W F ^a   Christiansen, Jane C ^a   Anderson, Keaven M ^a   Kannel, William B ^a  

^a FRAMINGHAM HEART STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

CARDIOVASCULAR DISEASE; HUMAN; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; ALGORITHMS; CHOLESTEROL; COHORT STUDIES; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMAN; LIPOPROTEINS, LDL; MALE; MIDDLE AGE; RISK FACTORS; UNITED STATES;

EID: 0024406675     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1989.03430010053030     Document Type: Article

References (15)

1. Lowering blood cholesterol to prevent heart disease. JAMA. 1985;253:2080-2086.
2. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988; 148:36-39.
3. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 1979;110:281-290.
4. New weight standards for men and women. Stat Bull Metrop Life Insur Co. 1959;40:1-4.
5. Shurtleff D. Some Characteristics Related to the Incidence of Cardiovascular Disease and Death: Framingham Study, 18 Year Followup. Washington, DC: Dept of Health, Education, and Welfare; 1974. Publication (NIH) 75-599.
6. Lipid Research Clinics Program. Manual of Laboratory Operation. Washington, DC: Dept of Health, Education, and Welfare; 1974;1. Publication (NIH) 75-628.
7. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta. 1987;166:1-5.
8. Warnick GR, Benderson JM, Albers JJ. Dextran-sulfate magnesium precipitation procedure for quantification of high-density-lipoprotein cholesterol. Clin Chem. 1982;28:1379-1383.
9. Wilson PWF, Castelli WP, Kannel WB. Coronary risk prediction in adults (the Framingham Heart Study). Am J Cardiol. 1987;59:91G-94G.
10. Havlik RJ, Feinleib M. Proceedings of the Conference on the Decline in Coronary Heart Disease Mortality: Bethesda, MD, October24-25, 1978. Bethesda, Md: National Heart, Lung, and Blood Institute; 1979. National Institutes of Health publication 79-1610.
11. Treatment of hypertriglyceridemia. JAMA. 1984;251:1196-1200.
12. The Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in the incidence of coronary heart disease. JAMA. 1984;251:351-364.
13. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1244.
14. Canner PL, Berge KG, Wenger NK, et al. Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
15. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA. 1987;257:2176-2180.